Figure 2

Treatment with TPD protects against TNBS colitis development.

Clinical colitis severity was monitored by weight loss (a), survival rate (b) (dexamethasone overlaps with the TPD 4 mg/kg curve and it is not apparent in the graph), clinical score (c), histopathologic analysis performed in hematoxylin/eosin-stained sections of colons (d), representative colons feature groups (e) (1- naïve, 2- PBS, 3- Dexamethasone, 4- TPD 1 mg/Kg, 5- TPD 4 mg/Kg) and histologic features of representative colonic sections at x10 magnification (f) of TNBS induced mice treated with either PBS, Dexamethasone as positive control and TPD 1 or 4 mg/Kg. *P < 0.05, n = 10 (Mean ± SEM, Student’s t test). Representative images of dissected organs (g) of TNBS treated or healthy mice sacrificed 2 h or 10 h after intravenous injection of fluorescently labeled TPD (1.5 nmol of TACE prodomain-HiLyte Fluor 750) or fluorescent dye only (1.5 nmol of Hilyte Fluor 750). (h) Colon-to-heart ratios of the fluorescence for the mice sacrificed 2 and 10 hours after injection.